Concord Biotech Shares Surge Following US FDA Approval of Tofacitinib Tablet

Concord Biotech saw its market price climb after receiving regulatory clearance. The US Food and Drug Administration approved the company's Tofacitinib tablets. Tofacitinib is used to treat certain autoimmune conditions. The approval marks a significant milestone for the Indian pharmaceutical firm. Business Standard reported the positive market reaction to the news. The company plans to launch the product in key therapeutic areas. No additional indications or pricing details were disclosed. Investors will watch the drug's commercial performance in upcoming quarters.